Therapeutic potential of injectable Nano-mupirocin liposomes for infections involving multidrug-resistant bacteria

Cern, Ahuva, Bavli, Yaelle, Hod, Atara, Zilbersheid, Daniel, Mushtaq, Shazad, Michael-Gayego, Ayelet, Barasch, Dinorah, Feinstein Rotkopf, Yael, Moses, Allon E., Livermore, David and Barenholz, Yechezkel (2021) Therapeutic potential of injectable Nano-mupirocin liposomes for infections involving multidrug-resistant bacteria. Pharmaceutics, 13 (12). ISSN 1999-4923

[img]
Preview
PDF (Published_Version) - Published Version
Available under License Creative Commons Attribution.

Download (707kB) | Preview

Abstract

Antibiotic resistance is a global health threat. There are a few antibiotics under development, and even fewer with new modes of action and no cross-resistance to established antibiotics. Accordingly, reformulation of old antibiotics to overcome resistance is attractive. Nano-mupirocin is a PEGylated nano-liposomal formulation of mupirocin, potentially enabling parenteral use in deep infections, as previously demonstrated in several animal models. Here, we describe extensive in vitro profiling of mupirocin and Nano-mupirocin and correlate the resulting MIC data with the pharmacokinetic profiles seen for Nano-mupirocin in a rat model. Nano-mupirocin showed no cross-resistance with other antibiotics and retained full activity against vancomycin-, daptomycin-, linezolid- and methicillin- resistant Staphylococcus aureus, against vancomycin-resistant Enterococcus faecium, and cephalosporin-resistant Neisseria gonorrhoeae. Following Nano-mupirocin injection to rats, plasma levels greatly exceeded relevant MICs for > 24 h, and a biodistribution study in mice showed that mupirocin concentrations in vaginal secretions greatly exceeded the MIC 90 for N. gonorrhoeae (0.03 µg/mL) for > 24 h. In summary, Nano-mupirocin has excellent potential for treatment of several infection types involving multiresistant bacteria. It has the concomitant benefits from utilizing an established antibiotic and liposomes of the same size and lipid composition as Doxil®, an anticancer drug product now used for the treatment of over 700,000 patients globally.

Item Type: Article
Faculty \ School: Faculty of Medicine and Health Sciences > Norwich Medical School
Depositing User: LivePure Connector
Date Deposited: 14 Dec 2021 13:31
Last Modified: 24 May 2022 14:44
URI: https://ueaeprints.uea.ac.uk/id/eprint/82674
DOI: 10.3390/pharmaceutics13122186

Actions (login required)

View Item View Item